The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Ionizing radiation damages chromosomal DNA and activates p53-dependent transcription in mammalian cells. The Chk2 protein kinase has been hypothesized to be the primary mediator of this response. We have rigorously tested this hypothesis in human cells by disrupting the CHK2 gene through homologous recombination. We found that the p53 response was unexpectedly robust in such cells. Phosphorylation of p53 at serine 20, accumulation of p53 protein, transcriptional activation of p53 target genes, and cell cycle arrest and apoptotic death phenotypes were completely intact regardless of CHK2 status. Our results indicate that Chk2 kinase is not required for p53 activation in human cells and explain why CHK2 and TP53 mutations can jointly occur in human tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The results in Figure 9C were unexpected since a previous study using the same HCT116-Chk2À/À cell line reported that Chk2 knockout did not affect p53 response to higher doses (12 Gy) of ionizing irradiation (Jallepalli et al, 2003).”
From ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage (2005) · cites this paper as Jallepalli et al, 2003
The cited source says what the claim attributes to it.
In the citing paper
“Although a role of ATM in p53 response is well established, the significance of Chk2 is still a matter of debate.”
From ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage (2005) · cites this paper as Jallepalli et al, 2003
In the citing paper
“A major caveat of this interpretation is that Chk2 does not seem to play an essential role in G2 arrest 84,85,72 and it is more likely that damaged cells progress into mitosis due to inefficient Chk1 activation 86 and/or lack of robust p21 induction.”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [85]
In the citing paper
“Studies using Chk2-null mice, Chk2-null HCT116 cells, and Chk2 siRNA resulted in different conclusions (Zhang et al, 1998;Chehab et al, 2000;Shieh et al, 2000;Ahn et al, 2003; Jallepalli et al, 2003).”
From ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage (2005) · cites this paper as Jallepalli et al, 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Self-citationRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Self-citationCell cycle checkpoint signaling through the ATM and ATR kinases
Abraham, R. T. (2001) · Genes & Development · doi:10.1101/gad.914401 · Cited by 1,966
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Self-citationLinkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase
Matsuoka, S. (1998) · Science · doi:10.1126/science.282.5395.1893 · Cited by 1,322
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2
Hirao, A., Kong, Y.-Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,285
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Self-citation
Research works printed but not linked: 8
- Dumaz, N., Milne, D. M., Jardine, L. J., and Meek, D. W. (2001) Biochem. J. 359, 459 -464 · doi:10.1042/bj3590459 · Paper page
- Lee, S. B., Kim, S. H., Bell, D. W., Wahrer, D. C., Schiripo, T. A., Jorczak, M. M., Sgroi, D. C., Garber, J. E., Li, F. P., Nichols, K. E., Varley, J. M., Godwin, A. K., Shannon, K. M., Harlow, E., and Haber, D. A. (2001) Cancer Res. 61, 8062-8067
- Canman, C. E., Wolff, A. C., Chen, C. Y., Fornace, A. J., Jr., and Kastan, M. B. (1994) Cancer Res. 54, 5054 -5058
- Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H., and Canman, C. E. (2000) Cancer Res. 60, 5934 -5936
- Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Cancer Res. 58, 1130 -1134
- Yu, Q., La Rose, J., Zhang, H., Takemura, H., Kohn, K. W., and Pommier, Y. (2002) Cancer Res. 62, 5743-5748
- Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995) Cancer Res. 55, 5187-5190
- Brown, K. D., Rathi, A., Kamath, R., Beardsley, D. I., Zhan, Q., Mannino, J. L., and Baskaran, R. (2002) Nat. Genet. 25, 25
Cited by
Items 101–158 of 158
BRCA1 is regulated by Chk2 in response to spindle damage
Chabalier-Taste, C., Racca, C., Dozier, C., & Larminat, F. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.08.006 · Cited by 32
“Targeted deletion of the human Chk2 locus in HCT116 cells was obtained through homologous recombination [29].”
MethodImproving the selectivity of cancer treatments by interfering with cell response pathways
Damia, G. L. M., & Broggini, M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.020 · Cited by 29
Lüddecke, S., Ertych, N., Stenzinger, A., Weichert, W., Beißbarth, T., Dyczkowski, J., Gaedcke, J., Valerius, O., Braus, G. H., Kschischo, M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.290 · Cited by 28
van Puijenbroek, M., van Asperen, C. J., van Mil, A., Devilee, P., van Wezel, T., & Morreau, H. M. (2005) · The Journal of Pathology · doi:10.1002/path.1764 · Cited by 28
“Manipulated HCT-116 human colon carcinoma cells carrying a homozygous deletion for CHEK2 yielded no defective phenotype with respect to p53, G1 or G2 cell-cycle arrest and apoptosis [27].”
BackgroundKim, W.-J., Beardsley, D. I., Adamson, A. W., & Brown, K. D. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.009 · Cited by 31
Running into problems: how cells cope with replicating damaged DNA
McGowan, C. H. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.08.011 · Cited by 36
Déry, U., & Masson, J. (2007) · DNA repair · doi:10.1016/j.dnarep.2006.12.009 · Cited by 30
Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity
Berge, E. O., Staalesen, V., Straume, A. H., Lillehaug, J. R., & Lønning, P. E. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.01.005 · Cited by 27
Bodakuntla, S., Anandi, L., V, Sural, S., Trivedi, P., & Lahiri, M. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-287 · Cited by 29
“Though it has been previously reported that the DLD1 cell line is Chk2 deficient [31], we could detect low amounts of phosphorylation of Chk2 at threonine 68 position in DLD1 cells which was reduced in presence of an ATM autophosphorylation inhibitor, KU 55933 (Figure 2D).”
BackgroundStolz, A., Ertych, N., & Bastians, H. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000693 · Cited by 25
Chen, Y., Miao, Z., Zhao, W., & Ding, J. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.053 · Cited by 25
Irofulven induces replication-dependent CHK2 activation related to p53 status
Wang, Y., Wiltshire, T. D., Senft, J., Reed, E., & Wang, W. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.023 · Cited by 28
“To further confirm these findings, the paired, isogenic colon cancer cell line HCT116 CHK2 +/+ and its CHK2-knockout cell line HCT116 CHK2−/− [44] were used.”
BackgroundMethodInfluentialReddy, V., Wu, M., Ciavattone, N. G., McKenty, N. T., Menon, M., Barrack, E. R., Reddy, G. P. V., & Kim, S.-H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.671404 · Cited by 25
“Interestingly, ATM-inactivation in normal cells has no untoward consequences (50).”
BackgroundLiang, X., Guo, Y., Figg, W. D., Fojo, A. T., Mueller, M. D., & Yu, J. (2010) · Chemotherapy Research and Practice · doi:10.1155/2011/715469 · Cited by 23
Cell cycle-dependent localization of CHK2 at centrosomes during mitosis
Chouinard, G., Clément, I., Lafontaine, J., Rodier, F., & Schmitt, E. (2013) · Cell Division · doi:10.1186/1747-1028-8-7 · Cited by 28
“To validate the specificity of these antibodies in immunofluorescence experiments, we used an isogenic human colorectal cancer HCT116 cell line with a targeted deletion of CHK2 [42].”
The roles of Chk 1 and Chk 2 in hypoxia and reoxygenation
Hammond, E. M., Freiberg, R. A., & Giaccia, A. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.06.029 · Cited by 24
“demonstrated that Chk 2 was not required for an irradiation induced G2 arrest in a human tumor line (HCT116) [23].”
BackgroundProcessing DNA lesions during mitosis to prevent genomic instability
Audrey, A., de Haan, L., van Vugt, M. A. T. M., & de Boer, H. R. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220049 · Cited by 23
The p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 24
Regulation of p53-dependent transcription
Jõers, A. (2004) · DSpace repository (University of Tartu) · Cited by 220
Mammalian DNA Damage Response Pathway
Lou, Z., & Chen, J. (2006) · Springer eBooks · doi:10.1007/1-4020-3764-3_15 · Cited by 22
Shionome, Y., Lin, W., Shiao, H., Hsieh, H., Hsu, J. T., & Ouchi, T. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.5806 · Cited by 17
“To study the roles of p53 pathway in Aurora-A tumorigenesis and BP-mediated tumor suppression, we used HCT116 human colorectal cancer cell line overexpressing Aurora-A (16), and its isogenic derivatives, in which p53-associated genes (p53, p21, Puma, Bax and Chk2) are stably knocked out in vitro [14-17].”
Beardsley, D. I., Kim, W.-J., & Brown, K. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013888 · Cited by 18
“HCT116 Chk2 / (Jallepalli et al., 2003) were obtained from Drs. B. Vogelstein and F. Bunz (Johns Hopkins Cancer Center, Baltimore, MD).”
BackgroundMethodInfluentialAnalysis of p53 Gene Alterations in Cancer: A Critical View
Soussi, T. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_12 · Cited by 18
Shionome, Y., Li, Y., Liu, S., Saeki, T., & Ouchi, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055457 · Cited by 12
hCCR4/cNOT6 targets DNA-damage response proteins
Sánchez‐Pérez, I., Manguán-García, C., Menacho-Márquez, M., Murguía, J. R., & Perona, R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.08.026 · Cited by 14
Nanoparticle-Mediated PRDX2 Inhibition for Specific Targeting of CHK2-Null Colorectal Cancer
Ahmad, A., Prakash, R., Khan, M. S., Altwaijry, N. A., Asghar, M. N., Raza, S. S., & Khan, R. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01073 · Cited by 11
14-3-3σ and p21 synergize to determine DNA damage response following Chk2 inhibition
Meng, S., Arbit, T., Veeriah, S., Mellinghoff, I. K., Fang, F., Vivanco, I., Rohle, D., & Chan, T. A.-T. (2009) · Cell Cycle · doi:10.4161/cc.8.14.8998 · Cited by 11
Distinct DNA damage determines differential phosphorylation of Chk2
Ouchi, M., & Ouchi, T. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972823 · Cited by 11
“Bert Vogelstein at Johns Hopkins University.(13) To induce DNA stress, 1 mg/ml of neocarzinostatin (Kayaku, Tokyo,”
BackgroundInfluentialBhonde, M., Hanski, M., Stehr, J., Jebautzke, B., Peiró‐Jordán, R., Fechner, H., Yokoyama, K. K., Lin, W., Zeitz, M., & HANSKI, C. (2009) · International Journal of Cancer · doi:10.1002/ijc.24893 · Cited by 9
Tissue-specific regulation of checkpoint kinase 2 expression by p53
Chin, M. Y., & Li, G. (2003) · Experimental and Molecular Pathology · doi:10.1016/s0014-4800(03)00088-1 · Cited by 7
Chk2 Protects against Radiation-Induced Genomic Instability
MacLaren, A., Slavin, D. A., & McGowan, C. H. (2009) · Radiation Research · doi:10.1667/rr1603.1 · Cited by 6
“It has been reported previously that Chk2 is not required for p53 responses in human cells (16).”
BackgroundInfluentialJiang, W., Bai, F., Wang, G., Liu, X., Peng, B., Xu, X., Nie, G., Zhu, W., Hu, B., & Pei, X. (2025) · Hearing Research · doi:10.1016/j.heares.2025.109369 · Cited by 4
DNA Damage Signaling Downstream of ATM
Bunz, F. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8044-1_2 · Cited by 5
“Studies in human cells demonstrate that p53 can be activated in the absence of Chk2 (Jallepalli et al. 2003), while analyses of knockout mice suggest that Chk2 is required for some p53dependent functions in some cells types (Jack et al.”
InfluentialSelf-citationPrinciples for the post-GWAS functional characterisation of risk lociPreprint
Monteiro, Á. N. A., Coetzee, G. A., Freedman, M. L., Biasi, M. D., Casey, G., Duggan, D., Risch, A., Plass, C., Liu, P., James, M. A., et al. (2010) · Nature Precedings · doi:10.1038/npre.2010.5162.1 · Cited by 4
Mutation in CHEK2 and hereditary breast cancer: A case report
Natalia, C. (2023) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2582 · Cited by 1
Cell Cycle Regulation and DNA Damage
Sakasai, R., & Tibbetts, R. S. (2009) · Springer eBooks · doi:10.1007/978-90-481-2561-6_5 · Cited by 1
P53 Links Tumor Development to Cancer Therapy
Hemann, M. T., & Lowe, S. W. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_15 · Cited by 2
“Also, chk2, which is important for DNA damage induced apoptosis in murine thymocytes, is dispensable for apoptosis in some tumors and cell lines (Ahn et al., 2003; Jallepalli et al., 2003 ).”
BackgroundCHK2 is Negatively Regulated by Protein Phosphatase 2A
Freeman, A. K. (2010) · Digital Commons - University of South Florida (University of South Florida)
Matthews, D. J., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch6
CHEK2 in Breast and Colorectal Cancer
Kilpivaara, O. (2007) · Työväentutkimus Vuosikirja
Novel Role of CHK2 in the Intrinsic and Extrinsic Apoptosis Pathway
Agarwal, A. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7ng4nnv
“On the other hand, loss of CHK2 in p53 deficient cancer cells has been shown to enhance apoptosis in response to DNA damage (Hirao et al., 2002; Jallepalli et al., 2003; Lovly et al., 2008a; Takai et al., 2002).”
InfluentialCharacterization of an autoimmune gene expression signature.
Maas, K. H. (2006)
Cell Cycle Responses to Hyperthermia
Furusawa, Y. (2016) · Springer eBooks · doi:10.1007/978-981-10-0719-4_6 · Cited by 2
Susceptibility genes in hereditary breast cancer
Vahteristo, P. (2003) · Helda - University of Helsinki Institutional Repository
The role of chromosomal instability in therapy response of colorectal cancer
Liu, X. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6575
Faculty Opinions recommendation of Ubiquitin-mediated proteolysis of HuR by heat shock.
DesGroseillers, L. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1160283.620594
POSTRANSLATIONAL MODIFICATIONS OF P53: UPSTREAM SIGNALING PATHWAYS.
ANDERSON, C. W. A., & (US), D. (2003) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.2172/15006423
Hoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Skuballa, W., Vivet, S., Lichtner, R. B., Vicencio, J. M., et al. (2023) · doi:10.1158/0008-5472.22375364.v1
Hoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Skuballa, W., Vivet, S., Lichtner, R. B., Vicencio, J. M., et al. (2023) · doi:10.1158/0008-5472.22375364
Posttranslational Modifications of p53: Upstream Signaling Pathways
Anderson, C. W., & Appella, E. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_5
Localisation et fonction de CHK2 en mitose
Chouinard, G. (2012) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/31174
Chimiothérapie ciblant les cellules cancéreuses p53 déficientes
Jèmaà, M. (2012) · theses.fr (ABES) · doi:10.70675/d5d7f17azc15cz4e7az80a7z617746909a2d
“%) est comparable à celui des mêmes cancers déficients en CHK2 (Williams et al, 2006 ; Jallepalli et al, 2003).”
BackgroundMécanismes orchestrant la sortie du cycle cellulaire opérant en G2
Lossaint, G. (2010) · theses.fr (ABES) · doi:10.70675/73a8a635z0ba0z466bza623zfba090ad12ce
Identification of New Oncogenes Involved in the Tumoral Progression of Breast Carcinoma
Mahmood, S. F. (2012) · theses.fr (ABES) · doi:10.70675/6245fe6cz59ebz47a0za5d9zed3f18e77455
Bačević, K. (2016) · theses.fr (ABES) · doi:10.70675/11789f75zbd23z4799zacfbzd7a0d55a3fd3
Caractérisation fonctionnelle de la tolérance aux endommagements de l’ADN des embryons précoces
Furno, E. L. (2019) · theses.fr (ABES) · doi:10.70675/cf32bcd5z3031z4693z8b1bz62fe76673ccc
Muñoz-Maldonado, C., Etter, R., Quintin, A., Degen, P. M., Medo, M., Aebersold, D. M., Zimmer, Y., & Medová, M. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03340-3
Development of novel therapies for colorectal carcinoma using dietary indoles
Brookes, A. (2014) · Figshare
Metadata
- Authors
- Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bunz, Fred
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-06
- Volume
- 278
- Issue
- 23
- Pages
- 20475-20479
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149938795
- Cited by
- 154
- References
- 45
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 5 · 2012: 1
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6342 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- National Institutes of Health (CA43460)
- National Cancer Institute (CA43460)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Chk2, p53, ionizing radiation response, p53 phosphorylation, cell cycle arrest, apoptosis, tumor suppressor, TP53 mutation, human cancer cells
- MeSH terms
- Colonic Neoplasms, DNA Damage, Exons, Humans, Phosphorylation, Protein Kinases, Tumor Cells, Cultured, Transcriptional Activation, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, G2 Phase, Protein Serine-Threonine Kinases, Checkpoint Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.